AASLD GUIDELINES Bundle (free trial)

Hepatitis B

AASLD GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/100168

Contents of this Issue

Navigation

Page 7 of 19

Treatment Patients who failed to achieve primary response as evidenced by < 2 log decrease in serum HBV DNA level after at least 6 months of NA therapy ����Switch to an alternative treatment or receive additional treatment. (III) Patients who develop breakthrough infection while receiving NA therapy (Table 5) ����Ascertain compliance and resume treatment in patients who have had long lapses in medications. (III) ����Perform confirmatory test for antiviral-resistant mutation if possible to differentiate primary nonresponse from breakthrough infection and to determine if there is evidence of multi-drug resistance (in patients who have been exposed to more than one NA treatment). (III) ��Consider all patients with virologic breakthrough for rescue therapy. (II-2) �� ����For patients in whom there was no clear indication for hepatitis B treatment and who continue to have compensated liver disease, consider withdrawal of therapy, but closely monitor these patients and reinitiate treatment if they experience severe hepatitis flares. (III) Lamivudine (or telbivudine)-resistant HBV ����If adefovir is used, continue lamivudine (or telbivudine) indefinitely to decrease the risk of hepatitis flares during the transition period and to reduce the risk of subsequent adefovir resistance. (II-3 for lamivudineresistant HBV and III for telbivudine-resistant HBV) ����If tenofovir is used, continue lamivudine (or telbivudine) to decrease the risk of subsequent antiviral resistance. (III) ����If entecavir is used, stop lamivudine or telbivudine since continued presence of lamivudine- (or telbivudine-) resistant mutations will increase the risk of entecavir resistance. (II-3 for lamivudine-resistant HBV and III for telbivudine-resistant HBV). Entecavir is not an optimal therapy because of increasing risk of resistance to entecavir over time. (II-2) 6

Articles in this issue

Archives of this issue

view archives of AASLD GUIDELINES Bundle (free trial) - Hepatitis B